CN1809539B - 有助于治疗由crth2介导的疾病的嘧啶衍生物 - Google Patents

有助于治疗由crth2介导的疾病的嘧啶衍生物 Download PDF

Info

Publication number
CN1809539B
CN1809539B CN2004800173378A CN200480017337A CN1809539B CN 1809539 B CN1809539 B CN 1809539B CN 2004800173378 A CN2004800173378 A CN 2004800173378A CN 200480017337 A CN200480017337 A CN 200480017337A CN 1809539 B CN1809539 B CN 1809539B
Authority
CN
China
Prior art keywords
amino
benzyl
acetic acid
pyrimidinyl
dimethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800173378A
Other languages
English (en)
Chinese (zh)
Other versions
CN1809539A (zh
Inventor
T·-W·利
Y·科里亚马
T·尤施诺
H·萨托
K·塔纳卡
H·苏吉莫托
Y·马纳布
K·培根
K·乌尔巴恩斯
M·塞基
T·欣塔尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GB007 Inc
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Publication of CN1809539A publication Critical patent/CN1809539A/zh
Application granted granted Critical
Publication of CN1809539B publication Critical patent/CN1809539B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2004800173378A 2003-04-25 2004-04-14 有助于治疗由crth2介导的疾病的嘧啶衍生物 Expired - Fee Related CN1809539B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03009384A EP1471057B1 (en) 2003-04-25 2003-04-25 Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2
EP03009384.3 2003-04-25
PCT/EP2004/003910 WO2004096777A1 (en) 2003-04-25 2004-04-14 Pyrimidine derivatives useful for the treatment of diseases mediated by crth2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010101716294A Division CN101914065A (zh) 2003-04-25 2004-04-14 有助于治疗由crth2介导的疾病的嘧啶衍生物

Publications (2)

Publication Number Publication Date
CN1809539A CN1809539A (zh) 2006-07-26
CN1809539B true CN1809539B (zh) 2012-05-09

Family

ID=32946880

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2004800173378A Expired - Fee Related CN1809539B (zh) 2003-04-25 2004-04-14 有助于治疗由crth2介导的疾病的嘧啶衍生物
CN2010101716294A Pending CN101914065A (zh) 2003-04-25 2004-04-14 有助于治疗由crth2介导的疾病的嘧啶衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010101716294A Pending CN101914065A (zh) 2003-04-25 2004-04-14 有助于治疗由crth2介导的疾病的嘧啶衍生物

Country Status (32)

Country Link
US (2) US7812160B2 (https=)
EP (2) EP1471057B1 (https=)
JP (2) JP4671955B2 (https=)
KR (1) KR101110491B1 (https=)
CN (2) CN1809539B (https=)
AR (1) AR043885A1 (https=)
AT (2) ATE316077T1 (https=)
AU (1) AU2004233966B2 (https=)
BR (1) BRPI0409733A (https=)
CA (1) CA2523439C (https=)
CL (1) CL43596B (https=)
CY (1) CY1111295T1 (https=)
DE (2) DE60303238T2 (https=)
DK (2) DK1471057T3 (https=)
DO (1) DOP2004000875A (https=)
ES (2) ES2257616T3 (https=)
GT (1) GT200400079A (https=)
HN (1) HN2004000129A (https=)
IL (1) IL171566A (https=)
MX (1) MXPA05011399A (https=)
MY (1) MY147984A (https=)
NO (1) NO20055588L (https=)
NZ (1) NZ543693A (https=)
PE (1) PE20050143A1 (https=)
PL (1) PL1633726T3 (https=)
PT (2) PT1471057E (https=)
RU (1) RU2361865C2 (https=)
SI (1) SI1633726T1 (https=)
TW (1) TWI353980B (https=)
UY (1) UY28286A1 (https=)
WO (1) WO2004096777A1 (https=)
ZA (1) ZA200508722B (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
PT1471057E (pt) 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
PL3718564T3 (pl) * 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
CN100584844C (zh) 2004-01-31 2010-01-27 艾克提麦斯医药品有限公司 咪唑[1,2-c]嘧啶基乙酸衍生物
US7714132B2 (en) 2004-03-11 2010-05-11 Actelion Pharmaceuticals, Ltd. Tetrahydropyridoindole derivatives
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
UY29223A1 (es) 2004-11-23 2006-06-30 Astrazeneca Ab Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
ZA200709817B (en) 2005-04-21 2009-02-25 Serono Lab 2,3 substituted pyrazine sulfonmides as inhibitors of CRTH2
PL1891075T3 (pl) 2005-05-24 2011-12-30 Merck Serono Sa Spiropochodne tricykliczne jako modulatory CRTH2
DOP2006000210A (es) * 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
EP1937632A1 (en) 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds
WO2007062677A1 (en) * 2005-11-30 2007-06-07 7Tm Pharma A/S Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands
AU2007256597A1 (en) * 2006-06-09 2007-12-13 Icos Corporation Substituted phenyl acetic acids as DP-2 antagonists
EP2132196A1 (en) 2007-02-26 2009-12-16 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
US8507005B2 (en) * 2007-06-21 2013-08-13 Actimis Pharmaceuticals, Inc. Particulates of a CRTH2 antagonist
EP2176240A1 (en) * 2007-06-21 2010-04-21 Actimis Pharmaceuticals, Inc., Amine salts of a crth2 antagonist
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
BRPI0817318A2 (pt) * 2007-09-25 2015-03-17 Actimis Pharmaceuticals Inc Composto, composição farmacêutica, e, método para tratar uma doença, ou uma condição, ou sintoma da mesma.
JP5524847B2 (ja) * 2007-09-25 2014-06-18 アクチミス ファーマシューティカルズ インコーポレーテッド Ｃｒｔｈ２アンタゴニストとしてのアルキルチオピリミジン
BRPI0907364A2 (pt) 2008-02-01 2015-07-14 Amira Pharmaceuticals Inc Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
WO2009102893A2 (en) 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
JP2011513242A (ja) 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体アンタゴニスト
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US8071807B2 (en) 2008-07-03 2011-12-06 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
US8541419B2 (en) 2008-09-02 2013-09-24 Actimis Pharmaceuticals, Inc. Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
SG172383A1 (en) * 2008-12-25 2011-07-28 Taisho Pharmaceutical Co Ltd Isoquinoline derivative
EP2393492A1 (en) * 2009-02-09 2011-12-14 Boehringer Ingelheim International GmbH New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
CA2751260A1 (en) 2009-02-12 2010-08-19 Stefano Crosignani Phenoxy acetic acid derivatives
WO2010094643A1 (en) * 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
EP2461809A4 (en) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
GB0913636D0 (en) * 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
US8815917B2 (en) 2009-08-05 2014-08-26 Panmira Pharmaceuticals, Llc DP2 antagonist and uses thereof
EA201200765A1 (ru) * 2009-11-24 2013-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения полиморфной модификации холиновой соли производного пиримидин-5-илуксусной кислоты
EP2521713A4 (en) 2010-01-06 2013-10-02 Panmira Pharmaceuticals Llc ANTAGONIST OF DP2 AND ITS USES
GEP20146177B (en) 2010-01-27 2014-10-10 Boehringer Ingelheim Int Pyrazole compounds as crth2 antagonists
MX2012014667A (es) 2010-06-23 2013-02-15 Taisho Pharma Co Ltd Derivado de isoquinolina.
CN102958914B (zh) 2010-07-05 2015-05-27 埃科特莱茵药品有限公司 1-苯基取代的杂环衍生物及其作为前列腺素d2受体调节剂的用途
JP2013535456A (ja) 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
JP2013535457A (ja) 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
MX346116B (es) 2010-10-20 2017-03-08 Valspar Sourcing Inc Sistema de revestimiento a base de agua con adhesion mejorada a una amplia variedad de sustratos revestidos y sin revestir, incluido el acero inoxidable de grado silenciador.
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US8759386B2 (en) 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
JP5999387B2 (ja) 2011-03-25 2016-09-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｒｔｈ２拮抗薬としてのピラゾール化合物
JP5988253B2 (ja) 2011-05-16 2016-09-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ［４，６−ビス−ジメチルアミノ−２−［４−（４−トリフルオロメチルベンゾイル−アミノ）ベンジル］ピリミジン−５−イル］酢酸の調製方法
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
TW201331179A (zh) 2011-12-21 2013-08-01 Actelion Pharmaceuticals Ltd 雜環衍生物及其作為前列腺素ｄ２受體調節劑之用途
CA2876808A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
WO2014079806A1 (en) 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrimidine compounds for treating hairloss
TWI695831B (zh) 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4239440A1 (https=) * 1991-12-04 1993-06-09 Imperial Chemical Industries Plc, London, Gb
EP1170594A2 (en) * 2000-07-07 2002-01-09 Pfizer Products Inc. Methods for the identification of compounds useful for the treatment of disease states mediated by Prostaglandin D2

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体
US6326368B1 (en) * 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
KR20000068354A (ko) * 1996-09-06 2000-11-25 다께다 가즈히꼬 신규 아세트아미드 유도체 및 프로테아제 저해제
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
HUP0301932A3 (en) * 2000-05-22 2007-09-28 Leo Pharma As Benzophenones as inhibitors of il-1 beta and tnf-alpha, pharmaceutical compositions containing them and use of them for producing pharmaceutical compositions
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP1413306A1 (en) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
PL377314A1 (pl) 2002-12-20 2006-01-23 Amgen Inc. Modulatory astmy i zapaleń na tle alergicznym
PT1471057E (pt) * 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
EP2176240A1 (en) 2007-06-21 2010-04-21 Actimis Pharmaceuticals, Inc., Amine salts of a crth2 antagonist
US8507005B2 (en) 2007-06-21 2013-08-13 Actimis Pharmaceuticals, Inc. Particulates of a CRTH2 antagonist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4239440A1 (https=) * 1991-12-04 1993-06-09 Imperial Chemical Industries Plc, London, Gb
EP1170594A2 (en) * 2000-07-07 2002-01-09 Pfizer Products Inc. Methods for the identification of compounds useful for the treatment of disease states mediated by Prostaglandin D2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EP 1170594 A2,说明书全文.

Also Published As

Publication number Publication date
KR101110491B1 (ko) 2012-01-31
DOP2004000875A (es) 2004-10-31
NO20055588D0 (no) 2005-11-25
PT1633726E (pt) 2011-02-22
PE20050143A1 (es) 2005-04-01
GT200400079A (es) 2004-11-30
AU2004233966A1 (en) 2004-11-11
JP5161290B2 (ja) 2013-03-13
WO2004096777A1 (en) 2004-11-11
EP1471057A1 (en) 2004-10-27
ES2358424T3 (es) 2011-05-10
US7812160B2 (en) 2010-10-12
PT1471057E (pt) 2006-05-31
JP2006524645A (ja) 2006-11-02
BRPI0409733A (pt) 2006-05-09
NZ543693A (en) 2009-05-31
DK1633726T3 (da) 2011-03-28
TWI353980B (en) 2011-12-11
EP1471057B1 (en) 2006-01-18
NO20055588L (no) 2006-01-24
CY1111295T1 (el) 2015-08-05
AU2004233966B2 (en) 2010-11-11
US20070129355A1 (en) 2007-06-07
DE602004030907D1 (de) 2011-02-17
TW200505873A (en) 2005-02-16
DE60303238D1 (de) 2006-04-06
ATE494279T1 (de) 2011-01-15
MY147984A (en) 2013-02-28
KR20060089622A (ko) 2006-08-09
RU2005136655A (ru) 2006-06-10
CA2523439C (en) 2012-06-19
SI1633726T1 (sl) 2011-04-29
HN2004000129A (es) 2009-05-14
HK1095320A1 (en) 2007-05-04
US20100322980A1 (en) 2010-12-23
RU2361865C2 (ru) 2009-07-20
JP4671955B2 (ja) 2011-04-20
EP1633726B1 (en) 2011-01-05
ZA200508722B (en) 2006-12-27
CN1809539A (zh) 2006-07-26
CA2523439A1 (en) 2004-11-11
US7960393B2 (en) 2011-06-14
DK1471057T3 (da) 2006-05-15
DE60303238T2 (de) 2006-09-14
JP2011068657A (ja) 2011-04-07
CL43596B (es) 2005-03-18
IL171566A (en) 2011-03-31
CN101914065A (zh) 2010-12-15
MXPA05011399A (es) 2006-05-31
AR043885A1 (es) 2005-08-17
PL1633726T3 (pl) 2011-06-30
EP1633726A1 (en) 2006-03-15
ES2257616T3 (es) 2006-08-01
ATE316077T1 (de) 2006-02-15
UY28286A1 (es) 2004-11-30

Similar Documents

Publication Publication Date Title
CN1809539B (zh) 有助于治疗由crth2介导的疾病的嘧啶衍生物
JP4996257B2 (ja) イミダゾ［１，２−ｃ］ピリミジニル酢酸誘導体
WO2005046698A1 (en) Fused heterocyclic compounds
WO2006014482A1 (en) Pyrimidine derivatives useful as inhibitors of pkc-theta
HK1095320B (en) Pyrimidine derivatives useful for the treatment of diseases mediated by crth2

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1095320

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1095320

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120509

Termination date: 20140414